Published in Br J Clin Pharmacol on June 01, 1989
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
Plasma propranolol levels in the quaniitative assessment of beta-adrenergic blockade in man. Br Med J (1970) 3.80
The assessment of beta-adrenoceptor blocking drugs in man. Br J Clin Pharmacol (1977) 3.13
Pharmacokinetic and pharmacodynamic studies with long-acting propranolol. Br J Clin Pharmacol (1978) 2.68
beta-Adrenoceptor blocking activity and duration of action of pindolol and propranolol in healthy volunteers. Br J Clin Pharmacol (1976) 2.17
A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol. Br J Clin Pharmacol (1976) 1.87
The effect on blood pressure of beta-adrenoceptor blocking drugs administered once daily and their duration of action when therapy is ceased. Br J Clin Pharmacol (1976) 1.80
Direct measurement of propranolol bioavailability during accumulation to steady-state. Br J Clin Pharmacol (1978) 1.60
Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol (1980) 1.55
The effects of changes in physical activity on major cardiovascular risk factors, hemodynamics, sympathetic function, and glucose utilization in man: a controlled study of four levels of activity. Circulation (1986) 1.37
Biological determinants of propranolol disposition in man. Clin Pharmacol Ther (1978) 1.35
Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med (1987) 1.34
The influence of cirrhosis on steady-state blood concentrations of unbound propranolol after oral administration. Clin Pharmacokinet (1979) 1.28
Correlation of plasma propranolol concentration with therapeutic response in patients with angina pectoris. Circulation (1975) 1.24
The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. Br J Clin Pharmacol (1983) 1.13
Pharmacology of propranolol in patients with cirrhosis and portal hypertension. Gut (1985) 1.07
Comparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension. Gut (1984) 1.00
Propranolol dosage, plasma concentration, and beta blockade. Clin Pharmacol Ther (1982) 0.95
Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a prospective study of factors associated with rebleeding. Hepatology (1987) 0.90
Assessment of beta blockade with propranolol. Clin Pharmacol Ther (1981) 0.86
A comparative pharmacokinetic study of conventional propranolol and long acting preparation of propranolol in patients with cirrhosis and normal controls. Br J Clin Pharmacol (1987) 0.84
Persistence of biologic activity after disappearance of propranolol from the serum. J Thorac Cardiovasc Surg (1976) 0.81
Effects of chronic administration of agonists and antagonists on the density of beta-adrenergic receptors. Am J Cardiol (1986) 0.80
[Study of bioavailability parameters of propranolol in cirrhotic patients after oral administration of the delayed-action form]. Therapie (1987) 0.78
Intrinsic hepatic clearance and Child-Turcotte classification for assessment of liver function in cirrhosis. J Hepatol (1985) 0.77
Relationship between dose, blood level and haemodynamic response in patients with cirrhosis receiving propranolol. Eur J Clin Pharmacol (1985) 0.77
Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie. N Engl J Med (1998) 4.93
Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol Psychiatry (2002) 2.87
Adverse event management in patients with advanced cancer receiving oral everolimus: focus on breast cancer. Ann Oncol (2014) 2.29
Prediction of the depressive effects of interferon alfa therapy by the patient's initial affective state. N Engl J Med (1999) 2.14
Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol (2009) 2.12
Severe portal hypertensive gastropathy and antral vascular ectasia are distinct entities in patients with cirrhosis. Gastroenterology (1995) 2.04
Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol (2002) 2.03
Taxane-induced glaucoma. Lancet (1999) 2.02
Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepat (2007) 1.94
Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology (2000) 1.67
Composition and dynamics of plasma in Saturn's magnetosphere. Science (2005) 1.66
Gastroesophageal endoscopic features in cirrhosis. Observer variability, interassociations, and relationship to hepatic dysfunction. Gastroenterology (1990) 1.60
Transient elastography accurately predicts presence of significant portal hypertension in patients with chronic liver disease. Aliment Pharmacol Ther (2008) 1.59
Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol (2004) 1.59
Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon alfa-2b therapy. J Clin Oncol (2000) 1.57
Genes of the major histocompatibility complex class II influence the outcome of hepatitis C virus infection. Gastroenterology (1997) 1.55
[Patient opinions after colonoscopy. Results of a cross sectional, multicenter ANGH study (2)]. Gastroenterol Clin Biol (2000) 1.47
Adjuvant therapy by BCG of non-Hodgkin's malignant lymphomas in a controlled trial: an update. Br J Haematol (1989) 1.39
Systemic and splanchnic hemodynamic effects of molsidomine in rats with carbon tetrachloride-induced cirrhosis. Hepatology (1991) 1.38
Association between immune activation and early depressive symptoms in cancer patients treated with interleukin-2-based therapy. Psychoneuroendocrinology (2001) 1.37
Propranolol in the prevention of first upper gastrointestinal tract hemorrhage in patients with cirrhosis of the liver and esophageal varices. N Engl J Med (1987) 1.34
Mutations in the MHC class I-like candidate gene for hemochromatosis in French patients. Immunogenetics (1997) 1.30
Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer (2011) 1.29
Inflammatory pseudotumor of the liver. Evidence for follicular dendritic reticulum cell proliferation associated with clonal Epstein-Barr virus. Am J Surg Pathol (1996) 1.27
Primary mediastinal large B-cell lymphoma. A clinicopathologic study of 141 cases compared with 916 nonmediastinal large B-cell lymphomas, a GELA ("Groupe d'Etude des Lymphomes de l'Adulte") study. Am J Surg Pathol (1996) 1.27
Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol (1992) 1.27
Endoscopic screening for esophageal squamous-cell carcinoma in high-risk patients: a prospective study conducted in 62 French endoscopy centers. Endoscopy (2006) 1.24
Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol (1998) 1.20
Timing and specificity of the cognitive changes induced by interleukin-2 and interferon-alpha treatments in cancer patients. Psychosom Med (2001) 1.20
Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension. Eur J Gastroenterol Hepatol (1999) 1.19
First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol (2008) 1.18
Nonstructural 3 protein of hepatitis C virus triggers an oxidative burst in human monocytes via activation of NADPH oxidase. J Biol Chem (2001) 1.15
Double-J ureteric stent encrustations: clinical study on crystal formation on polyurethane stents. Urol Int (1997) 1.14
Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J Virol (2000) 1.14
Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group. J Clin Oncol (1999) 1.14
Transjugular intrahepatic portosystemic shunt in the treatment of refractory bleeding from ruptured gastric varices. Hepatology (1999) 1.13
Incidence and management of mTOR inhibitor-associated pneumonitis in patients with metastatic renal cell carcinoma. Ann Oncol (2012) 1.12
The health data base of a nationwide company - its use in epidemiological studies. J Occup Med (1982) 1.11
Isolation of Thermus strains from hot composts (60 to 80 degrees C). Appl Environ Microbiol (1996) 1.10
Isolation and characterization of highly thermophilic xylanolytic Thermus thermophilus strains from hot composts. Can J Microbiol (2000) 1.09
Potential and realized feeding niches of neotropical hispine beetles (Chrysomelidae: Cassidinae, Cephaloleiini). Environ Entomol (2008) 1.08
Study of host- and virus-related factors associated with spontaneous hepatitis C virus clearance. Tissue Antigens (2000) 1.08
Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival--a Groupe d'Etude des Lymphomes de l'Adulte study on 453 patients older than 69 years. J Clin Oncol (1997) 1.06
KLF6 transcription factor protects hepatocellular carcinoma-derived cells from apoptosis. Cell Death Differ (2007) 1.06
Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol (1998) 1.04
[Natural history of esophageal varices in cirrhosis (from origin to rupture)]. Gastroenterol Clin Biol (1988) 1.04
Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer. Ann Oncol (2009) 1.03
Incidence of large oesophageal varices in patients with cirrhosis: application to prophylaxis of first bleeding. Gut (1990) 1.02
Oral Rh treatment for severely immunised mothers. Lancet (1979) 1.01
Genetic markers in chronic air-flow limitation. A genetic epidemiologic study. Am Rev Respir Dis (1983) 0.99
Increase of platelet thromboxane A2 formation and of its plasmatic half-life in diabetes mellitus. Thromb Res (1980) 0.99
Fulminant hepatitis due to cyproterone acetate. Lancet (1989) 0.98
Tyrosine kinase inhibition in renal cell carcinoma and gastrointestinal stromal tumours: case reports. Ann Oncol (2009) 0.97
A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy. Blood (1998) 0.97
Interactive effect of HLA and Gm tested in a study of 135 juvenile insulin-dependent diabetic families. Tissue Antigens (1986) 0.96
Hepatitis C virus genotype 5: epidemiological characteristics and sensitivity to combination therapy with interferon-alpha plus ribavirin. J Infect Dis (2004) 0.95
Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape. J Clin Oncol (1999) 0.94
Histopathologic analysis of transjugular intrahepatic portosystemic shunts. Hepatology (1997) 0.94
Assessment of short-term prognosis after variceal bleeding in patients with alcoholic cirrhosis by early measurement of portohepatic gradient. Hepatology (1986) 0.93
Reactive oxygen intermediates and eicosanoid production by kupffer cells and infiltrated macrophages in acute and chronic liver injury induced in rats by CCl4. Inflamm Res (2000) 0.93
[Livedoid vasculopathy (white atrophy) associated with anticardiolipin antibodies]. Ann Med Interne (Paris) (2000) 0.93
Transjugular intrahepatic portosystemic shunt: evaluation with Doppler sonography. Radiology (1993) 0.93
Bronchial carcinoid tumors: radiologic observations in 49 cases. J Thorac Imaging (1991) 0.92
Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha-interferon therapy. J Med Virol (1998) 0.91
Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia (2003) 0.91
Routinely performed multiparametric magnetic resonance imaging helps to differentiate common subtypes of renal tumours. Eur Radiol (2014) 0.90
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers. Eur J Cancer (2005) 0.90
Treatment of 150 ureteric calculi with the Lithoclast. Eur Urol (1994) 0.89
[Electrocardiographic changes during spontaneous angina crisis]. Arch Mal Coeur Vaiss (1969) 0.89
[Study of the exocrine function of the human pancreas, using continuous perfusions of secretin. I. Influence of increasing doses on secretion of water and electrolytes]. Arch Fr Mal App Dig (1969) 0.88
Influence of the ionic environment on the in vitro transcription of the spinach plastid DNA by a selectively bound RNA-polymerase DNA complex. Biochim Biophys Acta (1981) 0.87
Susceptibility to human cutaneous leishmaniasis and HLA, Gm, Km markers. Tissue Antigens (1987) 0.87
Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis. Br J Cancer (2012) 0.87
[Hepatitis C virus reinfection after an intravenous drug injection]. Gastroenterol Clin Biol (1998) 0.86
Expression of TNF-alpha and immunohistochemical distribution of hepatic macrophage surface markers in carbon tetrachloride-induced chronic liver injury in rats. Histochem J (1999) 0.86
Randomized phase II study of docetaxel plus estramustine and single-agent docetaxel in patients with metastatic hormone-refractory prostate cancer. Ann Oncol (2007) 0.86
Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer. Eur J Cancer (2003) 0.85
Vinorelbine/5-FU combination in metastatic breast cancer chemotherapy. A retrospective study of 63 cases. Eur J Cancer (1996) 0.85
Treatment of bleeding stomal varices using transjugular intrahepatic portosystemic shunt. J Pediatr Gastroenterol Nutr (1994) 0.85
Role of cholinergic mechanisms in the response to secretin of isolated canine pancreas. Gastroenterology (1975) 0.85
Color Doppler-US guidance in transjugular placement of intrahepatic portosystemic shunts. Radiology (1992) 0.85
Effects of catecholamines and their inhibitors on the isolated canine pancreas. II. Dopamine. Gastroenterology (1977) 0.84
[Mandibular osteosynthesis and compression]. Ann Chir Plast (1977) 0.84